Arnett DK, Blumenthal RS, Albert MA, et al., 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 140: e596–e646. https://doi.org/10.1161/CIR.0000000000000678

Sattar N, Gill JM, Alazawi W, 2020, Improving prevention strategies for cardiometabolic disease. Nat Med, 26: 320–325. https://doi.org/10.1038/s41591-020-0786-7

Bluher M, 2019, Obesity: Global epidemiology and pathogenesis. Nat Rev Endocrinol, 15: 288–298. https://doi.org/10.1038/s41574-019-0176-8

Joseph P, Leong D, McKee M, et al., 2017, Reducing the global burden of cardiovascular disease, Part 1: The epidemiology and risk factors. Circ Res, 121: 677–694. https://doi.org/10.1161/circresaha.117.308903

Barrera-Chimal J, Lima-Posada I, Bakris GL, et al., 2022, Mineralocorticoid receptor antagonists in diabetic kidney disease-mechanistic and therapeutic effects. Nat Rev Nephrol, 18: 56–70. https://doi.org/10.1038/s41581-021-00490-8

Belden Z, Deiuliis JA, Dobre M, et al., 2017, The role of the mineralocorticoid receptor in inflammation: Focus on kidney and vasculature. Am J Nephrol, 46: 298–314. https://doi.org/10.1159/000480652

Buonafine M, Bonnard B, Jaisser F, 2018, Mineralocorticoid receptor and cardiovascular disease. Am J Hypertens, 31: 1165–1174. https://doi.org/10.1093/ajh/hpy120 

Rossier BC, 2002, Hormonal regulation of the epithelial sodium channel enac: N or P(o)? J Gen Physiol, 120: 67–70. https://doi.org/10.1085/jgp.20028638

Rossier BC, Staub O, Hummler E, 2013, Genetic dissection of sodium and potassium transport along the aldosterone-sensitive distal nephron: Importance in the control of blood pressure and hypertension. FEBS Lett, 587: 1929–1941. https://doi.org/10.1016/j.febslet.2013.05.013

Ivanes F, Susen S, Mouquet F, et al., 2012, Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J, 33: 191–202. https://doi.org/10.1093/eurheartj/ehr176

Milliez P, Girerd X, Plouin PF, et al., 2005, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol, 45: 1243–1248. https://doi.org/10.1016/j.jacc.2005.01.015

Funder JW, 2004, Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol, 217: 263–269. https://doi.org/10.1016/j.mce.2003.10.054

Brown NJ, 2008, Aldosterone and vascular inflammation. Hypertension, 51: 161–167. https://doi.org/10.1161/hypertensionaha.107.095489 

Arriza JL, Weinberger C, Cerelli G, et al., 1987, Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science, 237: 268–275. https://doi.org/10.1126/science.3037703

Barrera-Chimal J, Jaisser F, 2019, Vascular mineralocorticoid receptor activation and disease. Exp Eye Res, 188: 107796. https://doi.org/10.1016/j.exer.2019.107796

Shibata S, Nagase M, Yoshida S, et al., 2008, Modification of mineralocorticoid receptor function by Rac1 GTpase: Implication in proteinuric kidney disease. Nat Med, 14: 1370–1376.https://doi.org/10.1038/nm.1879

Nagase M, Fujita T, 2013, Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol, 9: 86–98. https://doi.org/10.1038/nrneph.2012.282 

Hayashi T, Shibata H, Kurihara I, et al., 2017, High glucose stimulates mineralocorticoid receptor transcriptional activity through the protein kinase C β signaling. Int Heart J, 58: 794–802. https://doi.org/10.1536/ihj.16-649

Nagase M, Matsui H, Shibata S, et al., 2007, Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: Role of oxidative stress. Hypertension, 50: 877–883. https://doi.org/10.1161/hypertensionaha.107.091058 

Cole TJ, Young MJ, 2017, 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor null mice: Informing cell-type-specific roles. J Endocrinol, 234: T83–T92. https://doi.org/10.1530/joe-17-0155

Kolkhof P, Joseph A, Kintscher U, 2021, Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders-new perspectives for combination therapy. Pharmacol Res, 172: 105859. https://doi.org/10.1016/j.phrs.2021.105859

Usher MG, Duan SZ, Ivaschenko CY, et al., 2010, Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest, 120: 3350–3364. https://doi.org/10.1172/jci41080 

Sun JY, Li C, Shen ZX, et al., 2016, Mineralocorticoid receptor deficiency in macrophages inhibits neointimal hyperplasia and suppresses macrophage inflammation through SGK1-AP1/NF-κBpathways. Arterioscler Thromb Vasc Biol, 36: 874–885. https://doi.org/10.1161/atvbaha.115.307031

McCurley A, Pires PW, Bender SB, et al., 2012, Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med, 18: 1429–1433. https://doi.org/10.1038/nm.2891 

Nguyen Dinh A, Griol-Charhbili V, Loufrani L, et al., 2010, The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J, 24: 2454–2463. https://doi.org/10.1096/fj.09-147926

Mueller KB, Bender SB, Hong K, et al., 2015, Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension, 66: 988–997. https://doi.org/10.1161/hypertensionaha.115.06172

Sun XN, Li C, Liu Y, et al., 2017, T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma. Circ Res, 120: 1584–1597. https://doi.org/10.1161/circresaha.116.310480

Wu H, Ballantyne CM, 2020, Metabolic inflammation and insulin resistance in obesity. Circ Res, 126: 1549–1564. https://doi.org/10.1161/circresaha.119.315896

Ferreira NS, Tostes RC, Paradis P, et al., 2021, Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens, 34: 15–27. https://doi.org/10.1093/ajh/hpaa137

Van der Heijden C, Bode M, Riksen NP, et al., 2022, The role of the mineralocorticoid receptor in immune cells in cardiovascular disease. Br J Pharmacol, 179: 3135–3151. https://doi.org/10.1111/bph.15782

Moore KJ, Tabas I, 2011, Macrophages in the pathogenesis of atherosclerosis. Cell, 145: 341–355. https://doi.org/10.1016/j.cell.2011.04.005

Keidar S, Kaplan M, Pavlotzky E, et al., 2004, Aldosterone administration to mice stimulates macrophage nadph oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation, 109: 2213–2220. https://doi.org/10.1161/01.cir.0000127949.05756.9D 

Keidar S, Hayek T, Kaplan M, et al., 2003, Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol, 41: 955–963. https://doi.org/10.1097/00005344-200306000-00019

Shen ZX, Chen XQ, Sun XN, et al., 2017, Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis. J Biol Chem, 292: 925–935. https://doi.org/10.1074/jbc.M116.739243

Man JJ, Lu Q, Moss ME, et al., 2021, Myeloid mineralocorticoid receptor transcriptionally regulates p-selectin glycoprotein ligand-1 and promotes monocyte trafficking and atherosclerosis. Arterioscler Thromb Vasc Biol, 41: 2740–2755. https://doi.org/10.1161/atvbaha.121.316929 

Fraccarollo D, Thomas S, Scholz CJ, et al., 2019, Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing. Hypertension, 73: 102–111. https://doi.org/10.1161/hypertensionaha.118.12162

Rickard AJ, Morgan J, Tesch G, et al., 2009, Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension, 54: 537–543. https://doi.org/10.1161/hypertensionaha.109.131110 

Bienvenu LA, Morgan J, Rickard AJ, et al., 2012, Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology, 153: 3416–3425. https://doi.org/10.1210/en.2011-2098

Olefsky JM, Glass CK, 2010, Macrophages, inflammation, and insulin resistance. Annu Rev Physiol, 72: 219–246. https://doi.org/10.1146/annurev-physiol-021909-135846

Guo C, Ricchiuti V, Lian BQ, et al., 2008, Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation, 117: 2253–2261. https://doi.org/10.1161/circulationaha.107.748640

Wada T, Kenmochi H, Miyashita Y, et al., 2010, Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology, 151: 2040–2049. https://doi.org/10.1210/en.2009-0869

Zhang YY, Li C, Yao GF, et al., 2017, Deletion of macrophage mineralocorticoid receptor protects hepatic steatosis and insulin resistance through ERα/HGF/Met pathway. Diabetes, 66: 1535–1547. https://doi.org/10.2337/db16-1354 

Vinh A, Chen W, Blinder Y, et al., 2010, Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation, 122: 2529–2537. https://doi.org/10.1161/circulationaha.109.930446

Hevia D, Araos P, Prado C, et al., 2018, Myeloid CD11c+ antigen-presenting cells ablation prevents hypertension in response to angiotensin II plus high-salt diet. Hypertension, 71: 709–718. https://doi.org/10.1161/hypertensionaha.117.10145

Hengel FE, Benitah JP, Wenzel UO, 2022, Mosaic theory revised: Inflammation and salt play central roles in arterial hypertension. Cell Mol Immunol, 19: 561–576. https://doi.org/10.1038/s41423-022-00851-8

Herrada AA, Contreras FJ, Marini NP, et al., 2010, Aldosterone promotes autoimmune damage by enhancing TH17-mediated immunity. J Immunol, 184: 191–202. https://doi.org/10.4049/jimmunol.0802886

Amador CA, Barrientos V, Pena J, et al., 2014, Spironolactone decreases doca-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension, 63: 797–803. https://doi.org/10.1161/hypertensionaha.113.02883

Bene NC, Alcaide P, Wortis HH, et al., 2014, Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease. Steroids, 91: 38–45. https://doi.org/10.1016/j.steroids.2014.04.005 

Kirabo A, Fontana V, de Faria AP, et al., 2014, DC isoketal-modified proteins activate t cells and promote hypertension. J Clin Invest, 124: 4642–4656. https://doi.org/10.1172/JCI74084

Araos P, Prado C, Lozano M, et al., 2019, Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation. J Hypertens, 37: 1482–1492. https://doi.org/10.1097/HJH.0000000000002067

Buonafine M, Martinez-Martinez E, Amador C, et al., 2018, Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J Mol Cell Cardiol, 115: 32–38. https://doi.org/10.1016/j.yjmcc.2017.12.011 

Latouche C, El Moghrabi S, Messaoudi S, et al., 2012, Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension, 59: 966–972. https://doi.org/10.1161/hypertensionaha.111.187872

Guzik TJ, Hoch NE, Brown KA, et al., 2007, Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med, 204: 2449–2460. https://doi.org/10.1084/jem.20070657 

Itani HA, McMaster WG Jr., Saleh MA, et al., 2016, Activation of human T cells in hypertension: Studies of humanized mice and hypertensive humans. Hypertension, 68: 123–132. https://doi.org/10.1161/hypertensionaha.116.07237

Shen JZ, Young MJ, 2012, Corticosteroids, heart failure, and hypertension: A role for immune cells? Endocrinology, 153: 5692–5700. https://doi.org/10.1210/en.2012-1780 

Chu PY, Zatta A, Kiriazis H, et al., 2011, CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail, 4: 651–658. https://doi.org/10.1161/circheartfailure.110.960831

Li C, Sun XN, Zeng MR, et al., 2017, Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-cell activation. Hypertension, 70: 137–147. https://doi.org/10.1161/hypertensionaha.117.09070

Adamo L, Rocha-Resende C, Mann DL, 2020, The emerging role of B lymphocytes in cardiovascular disease. Annu Rev Immunol, 38: 99–121. https://doi.org/10.1146/annurev-immunol-042617-053104

McLaughlin T, Ackerman SE, Shen L, et al., 2017, Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest, 127: 5–13. https://doi.org/10.1172/JCI88876

Soehnlein O, Libby P, 2021, Targeting inflammation in atherosclerosis-from experimental insights to the clinic. Nat Rev Drug Discov, 20: 589–610. https://doi.org/10.1038/s41573-021-00198-1 

Pober JS, Sessa WC, 2007, Evolving functions of endothelial cells in inflammation. Nat Rev Immunol, 7: 803–815. https://doi.org/10.1038/nri2171

Poston RN, Haskard DO, Coucher JR, et al., 1992, Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol, 140: 665–673.

Iiyama K, Hajra L, Iiyama M, et al., 1999, Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res, 85: 199–207. https://doi.org/10.1161/01.res.85.2.199

Caprio M, Newfell BG, la Sala A, et al., 2008, Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res, 102: 1359–1367. https://doi.org/10.1161/circresaha.108.174235 

Marzolla V, Armani A, Mammi C, et al., 2017, Essential role of icam-1 in aldosterone-induced atherosclerosis. Int J Cardiol, 232: 233–242. https://doi.org/10.1016/j.ijcard.2017.01.013

Moss ME, Lu Q, Iyer SL, et al., 2019, Endothelial mineralocorticoid receptors contribute to vascular inflammation in atherosclerosis in a sex-specific manner. Arterioscler Thromb Vasc Biol, 39: 1588–1601. https://doi.org/10.1161/atvbaha.119.312954

Lother A, Furst D, Bergemann S, et al., 2016, Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension, 67: 130–138. https://doi.org/10.1161/hypertensionaha.115.06530 

Rickard AJ, Morgan J, Chrissobolis S, et al., 2014, Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension, 63: 1033–1040. https://doi.org/10.1161/hypertensionaha.113.01803

Laursen SB, Finsen S, Marcussen N, et al., 2018, Endothelial mineralocorticoid receptor ablation does not alter blood pressure, kidney function or renal vessel contractility. PloS One, 13: e0193032. https://doi.org/10.1371/journal.pone.0193032 

Zheng XJ, Liu Y, Zhang WC, et al., 2019, Mineralocorticoid receptor negatively regulates angiogenesis through repression of STAT3 activity in endothelial cells. J Pathol, 248: 438–451. https://doi.org/10.1002/path.5269

Kobayashi N, Fukushima H, Takeshima H, et al., 2010, Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. Am J Hypertens, 23: 1007–1013. https://doi.org/10.1038/ajh.2010.91

Zhao M, Mantel I, Gelize E, et al., 2019, Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nat Commun, 10: 369. https://doi.org/10.1038/s41467-018-08125-6

Hwang MH, Yoo JK, Luttrell M, et al., 2013, Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond), 125: 513–520. https://doi.org/10.1042/CS20130200

Schafer N, Lohmann C, Winnik S, et al., 2013, Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J, 34: 3515–3524. https://doi.org/10.1093/eurheartj/eht095

Jia G, Habibi J, DeMarco VG, et al., 2015, Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension, 66: 1159–1167. https://doi.org/10.1161/hypertensionaha.115.06015

Jia G, Habibi J, Aroor AR, et al., 2016, Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females. Circ Res, 118: 935–943. https://doi.org/10.1161/circresaha.115.308269 

Hassoun PM, 2021, Pulmonary arterial hypertension. N Engl J Med, 385: 2361–2376. https://doi.org/10.1056/NEJMra2000348

Maron BA, Leopold JA, 2015, Emerging concepts in the molecular basis of pulmonary arterial hypertension: Part II: Neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. Circulation, 131: 2079–2091. https://doi.org/10.1161/circulationaha.114.006980 

Omidkhoda N, Vakilian F, Mohammadpour AH, et al., 2020, Aldosterone and mineralocorticoid receptor antagonists on pulmonary hypertension and right ventricular failure: A review. Curr Pharm Des, 26: 3862–3870. https://doi.org/10.2174/1381612826666200523171137

Maron BA, Opotowsky AR, Landzberg MJ, et al., 2013, Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: A pilot study. Eur J Heart Fail, 15: 277–283. https://doi.org/10.1093/eurjhf/hfs173 

Calvier L, Legchenko E, Grimm L, et al., 2016, Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart, 102: 390–396. https://doi.org/10.1136/heartjnl-2015-308365

Preston IR, Sagliani KD, Warburton RR, et al., 2013, Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 304: L678–L688. https://doi.org/10.1152/ajplung.00300.2012

Boehm M, Arnold N, Braithwaite A, et al., 2018, Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulm Med, 18: 41. https://doi.org/10.1186/s12890-018-0604-x

Kowalski J, Deng L, Suennen C, et al., 2021, Eplerenone improves pulmonary vascular remodeling and hypertension by inhibition of the mineralocorticoid receptor in endothelial cells. Hypertension, 78: 456–465. https://doi.org/10.1161/hypertensionaha.120.16196 

Lacolley P, Regnault V, Nicoletti A, et al., 2012, The vascular smooth muscle cell in arterial pathology: A cell that can take on multiple roles. Cardiovasc Res, 95: 194–204. https://doi.org/10.1093/cvr/cvs135

Galmiche G, Pizard A, Gueret A, et al., 2014, Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension, 63: 520–526. https://doi.org/10.1161/hypertensionaha.113.01967

DuPont JJ, McCurley A, Davel AP, et al., 2016, Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging. JCI Insight, 1: e88942. https://doi.org/10.1172/jci.insight.88942 

Lu Q, Davel AP, McGraw AP, et al., 2019, PKCδ mediates mineralocorticoid receptor activation by angiotensin II to modulate smooth muscle cell function. Endocrinology, 160: 2101–2114. https://doi.org/10.1210/en.2019-00258 

Gueret A, Harouki N, Favre J, et al., 2016, Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension, 67: 717–723. https://doi.org/10.1161/hypertensionaha.115.06709

Kim SK, Biwer LA, Moss ME, et al., 2021, Mineralocorticoid receptor in smooth muscle contributes to pressure overload-induced heart failure. Circ Heart Fail, 14: e007279. https://doi.org/10.1161/circheartfailure.120.007279

Gourdie RG, Dimmeler S, Kohl P, 2016, Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nat Rev Drug Discov, 15: 620–638. https://doi.org/10.1038/nrd.2016.89 

Barrera-Chimal J, Girerd S, Jaisser F, 2019, Mineralocorticoid receptor antagonists and kidney diseases: Pathophysiological basis. Kidney Int, 96: 302–319. https://doi.org/10.1016/j.kint.2019.02.030

Stockand JD, Meszaros JG, 2003, Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol, 284: H176–H184. https://doi.org/10.1152/ajpheart.00421.2002

Wang Q, Cui W, Zhang HL, et al., 2013, Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2 in the genomic pathway. J Cardiovasc Pharmacol, 61: 520–527. https://doi.org/10.1097/FJC.0b013e31828c090e 

Fullerton MJ, Funder JW, 1994, Aldosterone and cardiac fibrosis: In vitro studies. Cardiovasc Res, 28: 1863–1867. https://doi.org/10.1093/cvr/28.12.1863

Brilla CG, Zhou G, Matsubara L, et al., 1994, Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol, 26: 809–820. https://doi.org/10.1006/jmcc.1994.1098

Lother A, Berger S, Gilsbach R, et al., 2011, Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension, 57: 746–754. https://doi.org/10.1161/hypertensionaha.110.163287

Fraccarollo D, Bauersachs J, 2011, Cardiomyocyte mineralocorticoid receptor function post myocardial infarction. Trends Cardiovasc Med, 21: 42–47. https://doi.org/10.1016/j.tcm.2012.02.003

Fraccarollo D, Berger S, Galuppo P, et al., 2011, Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation, 123: 400–408. https://doi.org/10.1161/circulationaha.110.983023

Bienvenu LA, Reichelt ME, Morgan J, et al., 2015, Cardiomyocyte mineralocorticoid receptor activation impairs acute cardiac functional recovery after ischemic insult. Hypertension, 66: 970–977. https://doi.org/10.1161/hypertensionaha.115.05981

He BJ, Joiner ML, Singh MV, et al., 2011, Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med, 17: 1610–1618. https://doi.org/10.1038/nm.2506

Ayoub IM, Kolarova J, Yi Z, et al., 2003, Sodium-hydrogen exchange inhibition during ventricular fibrillation: Beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resuscitability. Circulation, 107: 1804–1809. https://doi.org/10.1161/01.cir.0000058704.45646.0D

Rickard AJ, Morgan J, Bienvenu LA, et al., 2012, Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension, 60: 1443–1450. https://doi.org/10.1161/hypertensionaha.112.203158 

Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al., 2005 Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation, 111: 3025–3033. https://doi.org/10.1161/circulationaha.104.503706

Lother A, Bergemann S, Kowalski J, et al., 2018, Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity. Cardiovasc Res, 114: 282–290. https://doi.org/10.1093/cvr/cvx078 

Armani A, Marzolla V, Fabbri A, et al., 2015, Cellular mechanisms of mr regulation of adipose tissue physiology and pathophysiology. J Mol Endocrinol, 55: R1–R10. https://doi.org/10.1530/jme-15-0122

Caprio M, Feve B, Claes A, et al., 2007, Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J, 21: 2185–2194. https://doi.org/10.1096/fj.06-7970com

Hoppmann J, Perwitz N, Meier B, et al., 2010, The balance between gluco-and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol, 204: 153–164. https://doi.org/10.1677/JOE-09-0292 

Caprio M, Antelmi A, Chetrite G, et al., 2011, Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: Potential implications for the treatment of metabolic syndrome. Endocrinology, 152: 113–125. https://doi.org/10.1210/en.2010-0674

Lee MJ, Fried SK, 2014, The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes. Int J Obes (Lond), 38: 1228–1233. https://doi.org/10.1038/ijo.2014.6 

Hirata A, Maeda N, Hiuge A, et al., 2009, Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res, 84: 164–172. https://doi.org/10.1093/cvr/cvp191 

Urbanet R, Nguyen Dinh Cat A, Feraco A, et al., 2015, Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension, 66: 149–157. https://doi.org/10.1161/hypertensionaha.114.04981

Armani A, Cinti F, Marzolla V, et al., 2014, Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J, 28: 3745–3757. https://doi.org/10.1096/fj.13-245415

Wada T, Ishikawa A, Watanabe E, et al., 2017, Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance. J Endocrinol, 235: 179–191. https://doi.org/10.1530/joe-17-0351

Lefranc C, Friederich-Persson M, Braud L, et al., 2019, Mr (mineralocorticoid receptor) induces adipose tissue senescence and mitochondrial dysfunction leading to vascular dysfunction in obesity. Hypertension, 73: 458–468. https://doi.org/10.1161/hypertensionaha.118.11873

Nguyen Dinh Cat A, Antunes TT, Callera GE, et al., 2016, Adipocyte-specific mineralocorticoid receptor overexpression in mice is associated with metabolic syndrome and vascular dysfunction: Role of redox-sensitive PKG-1 and Rho kinase. Diabetes, 65: 2392–2403. https://doi.org/10.2337/db15-1627

Johansen ML, Ibarrola J, Fernandez-Celis A, et al., 2021, The mineralocorticoid receptor antagonist eplerenone suppresses interstitial fibrosis in subcutaneous adipose tissue in patients with Type 2 diabetes. Diabetes, 70: 196–203. https://doi.org/10.2337/db20-0394

Habibi J, Chen D, Hulse JL, et al., 2022, Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance. Am J Physiol Regul Integr Comp Physiol, 322: R253–R262. https://doi.org/10.1152/ajpregu.00316.2021

Ferguson D, Hutson I, Tycksen E, et al., 2020, Role of mineralocorticoid receptor in adipogenesis and obesity in male mice. Endocrinology, 161: bqz010. https://doi.org/10.1210/endocr/bqz010 

Lefranc C, Friederich-Persson M, Foufelle F, et al., 2021, Adipocyte-mineralocorticoid receptor alters mitochondrial quality control leading to mitochondrial dysfunction and senescence of visceral adipose tissue. Int J Mol Sci, 22: 2881. https://doi.org/10.3390/ijms22062881

Feraco A, Armani A, Urbanet R, et al., 2018, Minor role of mature adipocyte mineralocorticoid receptor in high fat induced obesity. J Endocrinol, 239: 229-240. https://doi.org/10.1530/joe-18-0314

Hayakawa T, Minemura T, Onodera T, et al., 2018, Impact of MR on mature adipocytes in high-fat/high-sucrose diet-induced obesity. J Endocrinol, 239: 63–71. https://doi.org/10.1530/joe-18-0026 

Kuhn E, Bourgeois C, Keo V, et al., 2014, Paradoxical resistance to high-fat diet-induced obesity and altered macrophage polarization in mineralocorticoid receptor-overexpressing mice. Am J Physiol Endocrinol Metab, 306: E75–E90. https://doi.org/10.1152/ajpendo.00323.2013 

Viengchareun S, Penfornis P, Zennaro MC, et al., 2001, Mineralocorticoid and glucocorticoid receptors inhibit ucp expression and function in brown adipocytes. Am J Physiol Endocrinol Metab, 280: E640–E649. https://doi.org/10.1152/ajpendo.2001.280.4.E640

Kuhn E, Lamribet K, Viengchareun S, et al., 2019, Ucp1 transrepression in brown fat in vivo and mineralocorticoid receptor anti-thermogenic effects. Ann Endocrinol (Paris), 80: 1–9. https://doi.org/10.1016/j.ando.2018.04.018

Marzolla V, Feraco A, Gorini S, et al., 2020, The novel non-steroidal mr antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via ampk-atgl pathway. FASEB J, 34: 12450–12465. https://doi.org/10.1096/fj.202000164R

Marzolla V, Feraco A, Limana F, et al., 2022, Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J Endocrinol Invest, 45: 215–220. https://doi.org/10.1007/s40618-021-01635-z

Thuzar M, Law WP, Dimeski G, et al., 2019, Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled cross-over study. Diabetes Obes Metab, 21: 509–516. https://doi.org/10.1111/dom.13539

Dirckx N, Morer MC, Clemens TL, et al., 2019, The role of osteoblasts in energy homeostasis. Nat Rev Endocrinol, 15: 651–665. https://doi.org/10.1038/s41574-019-0246-y 

Lee NK, Sowa H, Hinoi E, et al., 2007, Endocrine regulation of energy metabolism by the skeleton. Cell, 130: 456–469. https://doi.org/10.1016/j.cell.2007.05.047

Yi Y, Du L, Qin M, et al., 2019, Regulation of atrial fibrosis by the bone. Hypertension, 73: 379–389. https://doi.org/10.1161/hypertensionaha.118.11544

Wang YL, Bai L, Shi XR, et al., 2022, Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction. J Mol Cell Cardiol, 167: 40–51. https://doi.org/10.1016/j.yjmcc.2022.03.003 

Rico-Mesa JS, White A, Ahmadian-Tehrani A, et al., 2020, Mineralocorticoid receptor antagonists: A comprehensive review of finerenone. Curr Cardiol Rep, 22: 140. https://doi.org/10.1007/s11886-020-01399-7

Liu LC, Schutte E, Gansevoort RT, et al., 2015, Finerenone: Third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs, 24: 1123–1135. https://doi.org/10.1517/13543784.2015.1059819 

Kolkhof P, Borden SA, 2012, Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol Cell Endocrinol, 350: 310–317. https://doi.org/10.1016/j.mce.2011.06.025

Pitt B, Zannad F, Remme WJ, et al., 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med, 341: 709–717. https://doi.org/10.1056/NEJM199909023411001

Agarwal R, Kolkhof P, Bakris G, et al., 2021, Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J, 42: 152–161. https://doi.org/10.1093/eurheartj/ehaa736

McMurray JJ, O’Meara E, 2004, Treatment of heart failure with spironolactone--trial and tribulations. N Engl J Med, 351: 526–528. https://doi.org/10.1056/nejmp048144

Ko DT, Juurlink DN, Mamdani MM, et al., 2006, Appropriateness of spironolactone prescribing in heart failure patients: A population-based study. J Card Fail, 12: 205–210. https://doi.org/10.1016/j.cardfail.2006.01.003 

Wei L, Struthers AD, Fahey T, et al., 2010, Spironolactone use and renal toxicity: Population based longitudinal analysis. BMJ, 340: c1768. https://doi.org/10.1136/bmj.c1768

Vukadinovic D, Lavall D, Vukadinovic AN, et al., 2017, True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. Am Heart J, 188: 99–108. https://doi.org/10.1016/j.ahj.2017.03.011

Pitt B, Remme W, Zannad F, et al., 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 348: 1309–1321. https://doi.org/10.1056/nejmoa030207

Zannad F, McMurray JJ, Krum H, et al., 2011, Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 364: 11–21. https://doi.org/10.1056/NEJMoa1009492

Adamopoulos C, Ahmed A, Fay R, et al., 2009, Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: Insights from the ephesus trial. Eur J Heart Fail, 11: 1099–1105. https://doi.org/10.1093/eurjhf/hfp136

Montalescot G, Pitt B, Lopez de Sa E, et al., 2014, Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The randomized double-blind reminder study. Eur Heart J, 35: 2295–2302. https://doi.org/10.1093/eurheartj/ehu164

Filippatos G, Anker SD, Bohm M, et al., 2016, A randomized controlled study of finerenone vs. Eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J, 37: 2105–2114. https://doi.org/10.1093/eurheartj/ehw132

Bakris GL, Agarwal R, Anker SD, et al., 2020, Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes. N Engl J Med, 383: 2219–2229. https://doi.org/10.1056/NEJMoa2025845

Pitt B, Filippatos G, Agarwal R, et al., 2021, Cardiovascular events with finerenone in kidney disease and Type 2 diabetes. N Engl J Med, 385: 2252–2263. https://doi.org/10.1056/nejmoa2110956

Sueta D, Yamamoto E, Tsujita K, 2020, Mineralocorticoid receptor blockers: Novel selective nonsteroidal mineralocorticoid receptor antagonists. Curr Hypertens Rep, 22: 21. https://doi.org/10.1007/s11906-020-1023-y

Kintscher U, Bakris GL, Kolkhof P, 2022, Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol, 179: 3220–3234. https://doi.org/10.1111/bph.15747